≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback

Disorders of pituitary gland, other and/or unspecified

DOID EFO Endpoint Browser PheWeb

E4_PITUDISNAS

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E23.6, E23.7
  • Hospital discharge: ICD-9 — 253[8-9]
  • Hospital discharge: ICD-8 — 2539
  • Hospital discharge: excluded ICD-8 — 25390
  • Cause of death: ICD-10 — E23.6, E23.7
  • Cause of death: ICD-9 — 253[8-9]
  • Cause of death: ICD-8 — 2539
  • Cause of death: excluded ICD-8 — 25390

2 out of 7 registries used, show all original rules.

211

4. Check minimum number of events

None

211

5. Include endpoints

None

211

6. Filter based on genotype QC (FinnGen only)

211

Control definitions (FinnGen only)

Control exclude
E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1524 908 598
Only index persons 1235 751 484
Unadjusted period prevalence (%)
Whole population 0.02 0.03 0.02
Only index persons 0.02 0.03 0.02
Median age at first event (years)
Whole population 43.56 42.80 44.54
Only index persons 39.94 38.95 41.48

-FinnGen-

Key figures

All Female Male
Number of individuals 211 130 81
Unadjusted period prevalence (%) 0.04 0.04 0.04
Median age at first event (years) 42.83 40.75 46.15

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
182
Matched controls
1820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E23.6
ICD-10 Finland
Other disorders of pituitary gland
+∞
98.0
85
*
H02AB09
ATC
hydrocortisone; systemic
209.8
68.3
67
5
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
58.5
53
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
50.4
46
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
296.4
46.2
45
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
203.4
46.2
46
*
E23.7
ICD-10 Finland
Disorder of pituitary gland, unspecified
+∞
45.8
42
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
+∞
28.9
27
*
102
Kela drug reimbursment
Diabetes insipidus
+∞
27.8
26
*
H03AA01
ATC
levothyroxine sodium; systemic
5.7
24.4
90
267
25398
ICD-8 Finland
Diseases of pituitary gland, Alii definiti
+∞
23.4
22
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
50.2
22.1
26
6
25399
ICD-8 Finland
Diseases of pituitary gland, Other and unspecified
+∞
21.3
20
*
D44.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pituitary gland
+∞
21.3
20
*
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
19.1
18
*
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
11.6
17.6
33
34
N04BC06
ATC
cabergoline; oral (dopamine agonists)
+∞
16.9
16
*
H01AC01
ATC
somatropin; parenteral
+∞
15.9
15
*
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
15.9
15
*
E23.09
ICD-10 Finland
Pituitary insufficiency NOS
+∞
12.6
12
*
G02CB01
ATC
bromocriptine; systemic
19.8
12.3
18
10
301
Kela drug reimbursment
Growth hormone
+∞
11.6
11
*
AA4BG
NOMESCO Finland
MRI examination of sella turcica with high intensity magnet
127.7
11.6
12
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
11.6
10.6
19
18
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
116.4
10.5
11
*
E23.05
ICD-10 Finland
Lack of TSH
+∞
10.5
10
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.4
10.5
32
69
XCK00
NOMESCO Finland
Perimetry
5.6
8.4
24
48
2532A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Panhypopituitarism[PANHYPOPITUITARISMUS]
+∞
8.4
8
*
E23.01
ICD-10 Finland
Isolated deficiency of growth hormone
+∞
8.4
8
*
2538X
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Other disorders of the pituitary and other syndromes of diencephalohypophyseal origin[MORBUS HYPOPHYSEOS SEU HYPOTHALAMI ALIA]
+∞
8.4
8
*
25320
ICD-8 Finland
Diseases of pituitary gland, Chromophobe adenoma, pituitary
+∞
8.4
8
*
AA4CM
NOMESCO Finland
Extensive MRI examination of sella turcica with 3 Tesla magnet
+∞
8.4
8
*
E23.03
ICD-10 Finland
Lack of ACTH
+∞
8.4
8
*
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
83.3
7.5
8
*
2539X
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Unspecified
+∞
7.3
7
*
E23
ICD-10 Finland
Hypofunction and other disorders of pituitary gland
+∞
7.3
7
*
22620
ICD-8 Finland
Benign neoplasm of endocrine glands, Pituitary gland and craniopharyngeal duct (pouch)
+∞
7.3
7
*
ZXC86
NOMESCO Finland
Use of endoscopic device
41.6
6.8
8
*
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
+∞
6.3
6
*
D35.30
ICD-10 Finland
Craniopharyngoma
+∞
6.3
6
*
AA4DG
NOMESCO Finland
Very extensive MRI examination of sella turcica with high intensity magnet
+∞
6.3
6
*
E23.06
ICD-10 Finland
Empty sella
+∞
6.3
6
*
E23.08
ICD-10 Finland
Hypopituitarism
+∞
6.3
6
*
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
3.7
6.2
26
78
121
Kela drug reimbursment
Severe hypofunction of sexual glands
9.1
6.2
12
14

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
108
147
14.00
83.69
5.8
1.8
297.2
389.5
nmol/l
3.74
102
135
42
15
34.71
63.66
1.5
1.2
—
—
—
0
0
43
45
11.75
38.15
2.1
1.2
4.6
8.0
u/l
1.21
32
35
50
94
6.66
26.93
2.8
3.2
4.1
4.6
pmol/l
2.21
44
84
41
76
6.45
22.19
1.7
1.2
24.5
25.8
iu/l
0.07
26
65
49
119
5.06
19.68
5.3
2.0
10.7
14.2
nmol/l
2.49
44
110
15
17
9.42
12.15
4.4
1.4
—
—
—
0
0
40
122
3.81
11.65
5.6
3.0
1.2
1.2
mmol/l
0.77
35
107
13
13
10.59
11.45
1.4
1.2
—
—
—
0
0
131
818
2.59
10.08
6.7
5.7
29.2
28.2
%
0.40
126
757
130
812
2.57
9.95
6.0
5.5
56.9
56.9
%
0.01
125
757
13
16
8.59
9.84
2.2
1.6
33.1
31.7
pg
0.32
13
16
93
506
2.50
9.46
5.0
3.4
7.4
7.4
ph
0.87
30
90
120
735
2.47
9.39
12.2
5.7
1.2
1.2
mmol/l
0.12
111
671
18
34
5.69
9.34
1.4
1.4
—
—
—
0
0
126
793
2.46
9.23
12.9
6.6
1.2
1.2
mmol/l
0.04
95
665
126
794
2.46
9.19
6.6
5.7
2.5
2.8
%
0.81
119
734
126
797
2.44
9.07
6.7
5.9
8.8
8.4
%
0.45
121
742
122
769
2.39
8.74
6.7
5.7
0.6
0.7
%
0.20
117
710
37
130
3.24
8.59
4.9
4.0
—
—
—
0
0
65
311
2.58
8.55
4.0
2.7
500.9
539.6
mosm/kgh2o
0.60
55
262
133
882
2.37
8.32
6.1
5.6
1.9
2.0
e9/l
0.04
120
781
10
12
8.70
7.64
1.4
1.0
—
—
—
0
0
36
134
3.03
7.56
4.0
4.3
0.9
1.0
%
0.02
16
30
34
123
3.10
7.49
4.1
4.5
0.0
0.0
%
0.00
13
24
128
861
2.24
7.39
6.1
5.5
0.0
0.0
e9/l
0.10
112
747
34
124
3.08
7.39
4.1
4.5
0.1
0.1
%
0.35
14
27
112
716
2.20
7.32
7.8
4.6
35.5
36.0
g/l
0.37
104
672
92
545
2.22
7.26
6.5
5.4
—
—
—
0
0
127
860
2.20
7.11
6.1
5.5
0.6
0.6
e9/l
0.55
111
743
18
44
4.38
6.97
1.5
1.5
9.4
22.5
e6/l
0.63
12
38
18
44
4.38
6.97
1.3
1.3
58.3
3.2
e6/l
0.46
12
38
32
117
3.05
6.91
4.2
4.3
0.3
0.3
%
0.00
12
18
170
1311
2.53
6.79
8.0
3.9
15.2
14.8
pmol/l
1.06
163
1193
10
14
7.45
6.76
1.5
1.3
—
—
nmol/l
—
0
0
115
760
2.13
6.72
14.8
8.9
0.0
0.0
e9/l
0.30
97
617
128
886
2.13
6.56
6.3
5.7
0.2
0.2
e9/l
0.21
112
787
99
636
2.05
6.06
8.1
7.4
1.1
1.2
inr
0.46
38
187
10
16
6.51
6.01
1.5
1.3
—
—
—
0
0
137
1000
2.06
5.77
9.1
9.1
4.0
4.0
e9/l
0.07
122
873
13
30
4.55
5.37
3.8
1.8
16.2
16.5
%
—
6
10
10
18
5.78
5.37
1.5
1.7
—
—
—
0
0
11
22
5.22
5.32
6.5
1.5
—
—
—
0
0
33
141
2.59
5.32
1.4
1.3
—
—
—
0
0
45
228
2.24
4.99
3.5
2.1
2.3
2.4
g/l
0.63
40
207
165
1327
2.12
4.86
9.0
7.3
76.5
78.6
u/l
0.26
160
1239
44
229
2.16
4.55
1.2
1.3
—
—
—
0
0
66
405
1.92
4.33
5.7
4.8
—
—
—
0
0
72
457
1.87
4.25
4.3
3.0
0.3
0.3
e6/l
0.25
57
341
67
418
1.88
4.16
6.5
4.5
—
—
—
0
0
159
1292
1.94
4.14
4.7
4.0
12.1
11.3
mm/h
0.31
153
1188
41
217
2.10
4.04
3.5
2.2
19.2
22.5
%
0.97
36
186
12
33
3.80
3.98
9.2
1.5
—
—
—
0
0
183
1572
2.24
3.94
7.0
4.7
1.4
1.9
mu/l
6.65
169
1443
8
11
7.51
3.89
1.3
1.4
—
—
—
0
0
71
465
1.79
3.72
4.7
3.2
—
—
—
0
0
11
30
3.81
3.69
9.6
3.7
48.5
60.4
%
0.89
11
30
54
330
1.86
3.52
1.8
1.7
496.6
451.0
pmol/l
0.51
48
280
6
7
8.78
3.28
1.0
1.1
—
—
—
0
0
9
19
4.90
3.27
4.9
4.1
0.7
1.3
%
—
9
14
74
508
1.70
3.22
4.5
3.0
27.4
158.1
e6/l
0.51
58
387
91
664
1.65
3.12
2.0
1.9
95.8
97.9
pmol/l
0.16
47
325
7
12
5.99
3.04
1.4
1.1
2.2
1.8
mmol/l
—
7
12
40
232
1.89
3.04
2.9
2.2
—
—
—
0
0
9
21
4.43
3.03
2.7
1.5
86.6
89.7
%
—
9
21
5
5
10.20
2.99
1.2
3.2
2190.0
2459.0
ml
—
5
5
10
30
3.45
2.94
1.2
1.2
—
—
—
0
0
10
30
3.45
2.94
8.0
3.1
4.1
5.0
e9/l
—
10
30
25
124
2.15
2.90
3.4
2.5
71.1
70.1
e9/l
0.05
20
90
143
1183
1.65
2.87
5.9
4.3
—
—
—
0
0
8
19
4.33
2.70
3.6
1.3
—
—
—
0
0
51
333
1.70
2.61
4.0
2.4
5.1
4.6
e6/l
0.17
46
296
65
454
1.62
2.57
4.4
2.8
—
—
—
0
0
31
176
1.89
2.51
21.5
9.8
0.6
1.5
mmol/l
0.48
26
141
56
381
1.64
2.45
1.5
1.7
0.8
1.2
mg/l
1.05
40
293
31
179
1.86
2.39
2.5
1.6
—
—
—
0
0
7
17
4.22
2.38
2.3
3.0
—
—
—
0
0
77
572
1.55
2.31
4.9
3.4
2.3
2.4
mmol/l
0.72
68
498
107
854
1.51
2.30
5.0
3.6
0.0
0.0
estimate
0.00
33
142
65
469
1.56
2.21
2.6
3.1
700.5
200.0
mg/l
0.32
41
285
6
14
4.38
2.16
1.3
1.1
—
—
—
0
0
106
852
1.49
2.16
4.9
3.5
0.0
0.0
estimate
0.00
31
152
32
193
1.78
2.15
1.2
1.4
—
—
—
0
0
44
292
1.64
2.10
1.8
1.6
1324.7
1159.9
nmol/l
0.51
35
212
105
846
1.48
2.09
7.3
4.8
0.0
0.0
estimate
0.00
32
152
14
63
2.31
2.06
1.1
2.2
1.7
1.5
g/l
0.25
14
52
37
239
1.66
1.96
1.4
1.4
280.0
458.9
titre
—
6
53
78
599
1.48
1.95
5.0
3.6
17.6
93.2
e6/l
1.00
59
420
140
1205
1.48
1.93
4.1
3.6
—
—
—
0
0
34
217
1.68
1.89
2.1
2.4
112.5
120.8
ug/g
0.10
25
172
69
521
1.48
1.86
2.3
2.1
—
—
—
0
0
9
193
0.44
1.84
1.7
1.4
—
—
—
0
0
8
29
2.83
1.81
1.6
1.2
—
—
—
0
0
66
497
1.48
1.80
3.9
3.8
1.3
9.3
mg/mmol
4.31
45
306
54
392
1.51
1.75
1.3
1.2
0.8
1.0
u/ml
0.31
16
105
18
97
1.94
1.72
1.3
1.2
—
—
—
0
0
177
1615
1.60
1.71
6.5
5.4
39.9
39.7
mmol/mol
0.08
170
1513
23
135
1.79
1.71
2.7
2.6
0.2
0.2
g/l
0.68
23
124
21
120
1.83
1.69
1.4
1.5
—
—
—
0
0
6
19
3.22
1.67
1.2
1.2
—
—
—
0
0
7
25
2.86
1.66
1.7
1.9
—
—
—
0
0
40
275
1.56
1.66
2.0
1.8
—
—
—
0
0
5
14
3.63
1.62
1.0
1.1
—
—
—
0
0
49
356
1.49
1.58
1.4
1.3
2.4
2.5
g/l
0.04
33
205
20
116
1.80
1.55
1.2
1.2
158.5
167.6
iu/ml
—
8
42
67
520
1.42
1.54
3.0
2.9
7.4
7.7
mmol/l
0.15
62
436
11
51
2.22
1.53
2.3
1.6
—
—
—
0
0
11
51
2.22
1.53
1.2
1.2
—
—
—
0
0
29
188
1.63
1.53
1.6
1.6
—
—
—
0
0
6
21
2.91
1.51
4.5
1.8
—
—
—
0
0
21
126
1.74
1.46
2.1
2.2
61.7
67.3
g/l
1.82
21
115
7
28
2.55
1.46
1.1
1.3
—
—
—
0
0
5
16
3.17
1.44
1.8
1.1
—
—
—
0
0
6
22
2.78
1.44
1.3
1.3
—
—
—
0
0
62
485
1.39
1.34
5.7
3.0
—
—
—
0
0
29
195
1.56
1.33
7.1
6.2
106.2
103.8
mmol/l
1.41
29
189
14
77
1.88
1.29
9.4
2.8
5.2
5.0
kpa
0.40
14
71
14
77
1.88
1.29
35.8
15.2
—
—
—
0
0
56
435
1.39
1.26
6.9
7.0
—
—
—
0
0
10
50
2.05
1.18
5.1
3.1
—
—
—
0
0
58
458
1.37
1.18
5.2
3.8
0.0
0.0
estimate
0.00
31
152
5
20
2.53
1.16
3.0
2.3
—
—
—
0
0
5
20
2.53
1.16
3.6
4.3
—
—
—
0
0
59
469
1.36
1.15
4.7
3.6
—
—
—
0
0
42
316
1.41
1.13
4.7
2.8
2.4
2.4
mmol/l
1.06
37
280
17
104
1.69
1.13
1.1
1.2
—
—
—
0
0
7
31
2.30
1.11
5.7
1.6
25.0
24.0
mmol/l
—
7
24
20
129
1.61
1.10
10.3
7.6
—
—
—
0
0
81
680
1.31
1.09
2.1
1.9
—
—
—
0
0
53
418
1.36
1.09
2.2
2.5
362.8
4574.0
umol/l
1.52
43
350
185
1746
1.48
1.08
22.3
13.5
21.2
22.4
mg/l
0.21
164
1372
15
91
1.70
1.03
1.3
1.3
93.8
216.0
u/ml
1.12
15
80
29
209
1.45
0.99
2.8
2.6
6.0
7.7
umol/l
0.50
24
182
9
50
1.83
0.98
12.8
2.2
1.5
1.5
mg/l
—
9
43
76
644
1.28
0.93
5.4
3.4
27.8
38.6
ng/l
0.65
54
425
41
321
1.34
0.88
4.1
3.5
51.5
230.6
ng/l
1.47
28
248
22
155
1.47
0.85
27.4
10.5
96.6
96.2
%
0.23
22
149
21
147
1.48
0.84
28.9
11.0
116.1
122.3
g/l
0.95
21
142
0
25
0.00
0.79
0.0
1.0
—
—
—
0
0
5
24
2.11
0.75
1.6
1.3
343.8
285.1
u/ml
—
5
12
30
230
1.35
0.75
1.9
1.6
—
—
—
0
0
9
56
1.63
0.73
11.1
3.1
—
—
—
0
0
16
109
1.51
0.73
1.5
1.5
1.2
1.4
g/l
0.35
16
100
19
139
1.40
0.63
1.5
1.8
—
—
—
0
0
28
221
1.31
0.59
2.3
1.4
—
—
—
0
0
176
1686
1.26
0.59
5.0
4.4
5.8
5.9
mmol/l
1.07
167
1555
24
186
1.33
0.57
1.3
1.2
—
—
—
0
0
11
73
1.53
0.57
1.2
1.2
—
—
—
0
0
21
160
1.35
0.56
8.5
4.1
—
—
—
0
0
15
110
1.39
0.50
1.5
2.0
—
—
—
0
0
13
93
1.42
0.49
5.1
3.5
—
—
—
0
0
172
1653
1.22
0.49
4.5
3.9
1.4
1.3
mmol/l
1.42
164
1522
7
46
1.54
0.49
7.3
5.0
—
—
—
0
0
191
1857
1.30
0.48
13.5
10.0
31.6
26.5
u/l
0.51
186
1802
8
120
0.65
0.47
1.8
1.4
—
—
—
0
0
7
49
1.44
0.46
67.3
15.3
1.1
1.2
mmol/l
—
7
42
12
86
1.42
0.45
3.0
2.2
—
—
—
0
0
19
148
1.31
0.45
1.2
1.2
—
—
—
0
0
46
399
1.20
0.45
4.3
3.4
—
—
—
0
0
198
1937
1.36
0.44
32.3
19.4
258.1
252.2
e9/l
0.46
191
1898
12
87
1.40
0.43
1.4
1.8
—
—
—
0
0
198
1938
1.35
0.42
32.1
19.4
4.5
4.5
e12/l
0.65
191
1890
198
1938
1.35
0.42
32.2
19.5
6.8
6.6
e9/l
1.01
191
1891
5
33
1.53
0.41
1.0
1.1
—
—
—
0
0
5
33
1.53
0.41
1.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
12.2
—
782.1
—
0
15
0
15
0.00
0.41
0.0
15.5
—
1251.0
—
0
15
0
16
0.00
0.41
0.0
2.9
—
—
—
0
0
11
80
1.40
0.39
1.0
1.1
—
—
—
0
0
20
163
1.25
0.35
1.8
1.7
—
—
—
0
0
6
46
1.31
0.33
3.0
1.5
—
—
—
0
0
155
1601
0.88
0.31
23.1
14.5
38.5
40.3
%
1.27
115
1202
180
1756
1.17
0.30
5.3
4.8
2.7
2.8
mmol/l
0.93
174
1627
71
657
1.12
0.30
3.7
2.7
—
—
—
0
0
35
395
0.86
0.30
5.5
3.4
1.0
1.0
kg/l
—
6
52
8
65
1.24
0.27
2.4
1.3
—
—
—
0
0
8
66
1.22
0.27
2.4
1.3
—
—
—
0
0
8
66
1.22
0.27
2.4
1.3
—
—
—
0
0
8
66
1.22
0.27
2.4
1.3
—
—
—
0
0
21
179
1.19
0.26
1.2
1.5
—
—
—
0
0
10
78
1.30
0.24
1.7
2.0
—
—
—
0
0
5
39
1.29
0.23
12.8
3.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
3.2
—
—
—
0
0
0
12
0.00
0.21
0.0
7.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
28
252
1.13
0.19
3.1
2.6
0.9
0.6
ug/l
0.49
19
149
7
58
1.21
0.18
4.4
1.6
1.6
5.9
ug/l
—
7
50
52
487
1.09
0.17
1.7
1.7
1.4
1.4
mmol/l
0.05
44
424
7
62
1.13
0.17
1.3
1.1
—
—
—
0
0
185
1823
1.12
0.17
23.4
12.2
—
—
—
0
0
175
1723
1.09
0.15
5.0
4.3
4.6
4.7
mmol/l
0.90
168
1607
12
103
1.18
0.14
40.6
8.6
—
—
—
0
0
32
297
1.09
0.13
1.3
1.2
1.1
8.0
u/ml
2.60
12
129
15
169
0.88
0.13
1.5
1.5
—
—
—
0
0
11
125
0.87
0.10
1.5
1.4
—
—
—
0
0
19
174
1.10
0.10
4.6
4.1
232.1
8.1
ug/l
0.46
14
142
5
48
1.04
0.09
2.2
2.3
—
—
—
0
0
5
48
1.04
0.09
1.4
1.2
—
—
—
0
0
19
206
0.91
0.09
10.9
23.5
1.0
1.4
inr
—
5
28
6
54
1.11
0.09
2.8
1.2
—
—
—
0
0
173
1711
1.06
0.09
4.8
4.3
1.4
1.5
mmol/l
2.53
168
1586
5
65
0.76
0.08
3.2
12.8
—
—
—
0
0
7
64
1.10
0.08
67.0
12.6
1.3
1.6
%
—
7
59
7
65
1.08
0.08
4.9
3.6
—
—
—
0
0
12
130
0.92
0.04
4.8
3.2
—
—
—
0
0
12
129
0.93
0.03
5.8
3.9
—
—
—
0
0
13
126
1.03
0.00
3.2
3.0
—
—
—
0
0
45
445
1.01
0.00
1.5
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
5.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
8
87
0.92
0.00
3.4
2.3
0.6
0.7
%
—
8
87
7
75
0.93
0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
1.7
—
0
6
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
6
63
0.95
0.00
2.8
1.3
—
—
—
0
0
5
53
0.94
0.00
3.2
3.5
3.6
3.8
mmol/l
—
5
48
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
5
52
0.96
0.00
2.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
9.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
9
91
0.99
0.00
4.6
2.5
0.1
0.1
e6/l
—
9
85
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
9
90
1.00
0.00
4.3
2.3
1.6
1.3
%
—
9
90
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_PITUDISNAS and mortality.

Females

Parameter HR [95% CI] p-value
E4_PITUDISNAS 2.384 [1.81, 3.14] < 0.001
Birth year 0.992 [0.98, 1.0] 0.063

During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 396 females with E4_PITUDISNAS died.

Males

Parameter HR [95% CI] p-value
E4_PITUDISNAS 1.387 [0.99, 1.95] 0.06
Birth year 0.989 [0.98, 1.0] 0.015

During the follow-up period (1.1.1998 — 31.12.2019), 55 out of 288 males with E4_PITUDISNAS died.

Mortality risk

Mortality risk for people of age

years, who have E4_PITUDISNAS.

N-year risk Females Males
1 0.202% 0.217%
5 1.248% 1.664%
10 3.13% 4.363%
15 5.77% 8.112%
20 10.357% 13.946%

Relationships between endpoints

↥

Index endpoint: E4_PITUDISNAS – Disorders of pituitary gland, other and/or unspecified

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data